This week, Aureus Pharma said that it would continue its operations as Aureus Sciences, a name that it claims more accurately reflects its activities, and simultaneously launched a new web portal that grants entry to the company's cache of drug discovery tools and information.
In a statement, Jason Theodosiou, president and CEO of Aureus Sciences, said that the portal represents the first time that the company has offered "single-point access to all of our tools, applications, notes, scientific communications and technical documentation."
Aureus said that the web portal is built around a knowledge platform that analyzes, indexes, and organizes both chemical and bioactivity information of the druggable genome into scientific databases that can be used by researchers involved in drug discovery.
The portal gives clients, such as medicinal chemists, pharmacologists, and drug metabolism and pharmacokinetics scientists, access to Aureus' editorial content, applications, and community networks.
Users can conduct searches in Aureus’ knowledgebases, which contain more than 3 million biological activities, and filter results based on compound activity, therapeutic target affinity, ADME properties, or drug-drug interaction. The portal displays the results of the searches via a selection of “dashboards."
New customers can receive access to the full system under a named user license agreement while registered users can use the portal for more in-depth searches free of charge for a limited period of the time.